Acumen Pharmaceuticals (ABOS)
(Delayed Data from NSDQ)
$1.35 USD
-0.05 (-3.57%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $1.35 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ABOS 1.35 -0.05(-3.57%)
Will ABOS be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ABOS based on the 1-3 month trading system that more than doubles the S&P 500.
Other News for ABOS
ABOS: Acumen Pharmaceuticals Cuts Clinical Trial Costs with Innovative Assay
Acumen Pharmaceuticals Presents Studies Showing the Utility of a pTau217 Assay in Screening for ...
Acumen presents results from its Phase 2 ALTITUDE-AD study of sabirnetug
Tesla, Alphabet Set To Report Earnings As Investors Watch Out For Jobless Claims And Durable Goods Orders
Catalyst Watch: Alphabet earnings, McGraw Hill IPO, Trump talks AI, and more robotaxi buzz